POLY MEDICURE LTD. Q3 FY25 Results

We are extremely pleased with our continued growth in the business in the last quarter. Overall revenue grew by almost 25% with EBITDA and PAT growing by 28% and 31% respectively. We are on track to achieve our revenue growth guidance of 22-24% while improving our EBITDA margin by 100 — 150BPS. lam very excited to share that we have received regulatory approval to launch our Drug Eluting Stent and commercialisation of that is expected soon. That will give an significant fillip to our Cardiology business. We continue to invest aggressively in building our manufacturing capacities and recently ground-breaking ceremony was held at our Palwal Plant, which will be the largest plant that we would be setting up at a single location. We have also signed a JV agreement to set up a 1OMW Solar Power plant in Haryana where we will own 26% stake. This will go a long way in achieving our sustainability goals and reduce our carbon-footprint. We are very excited about the growth opportunity that India provides in the MedTech sector and our continued investments strongly reflects in that belief.